{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-002009","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.841921+00:00","generated_at":"2026-05-24T00:47:43.188272+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"RenovoRx reports first RenovoCath revenue of $43k in Q4 2024; TIGeR-PaC trial 79% enrolled","bullets":["First commercial RenovoCath revenue ~$43k in Q4 2024; sequential growth expected in 2025.","TIGeR-PaC trial: 90 of 114 patients randomized; 50 of 86 events; 2nd interim analysis at 52nd event expected Q2 2025.","Cash $7.2M at 2024 year-end; $10.9M net raised in Feb 2025 public offering.","Net loss $8.8M in 2024 vs $10.2M in 2023; R&D $6.0M, SG&A $5.0M.","Shares outstanding 36.5M as of March 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-002009","json":"https://secwatch.observer/filing/0001641172-25-002009.json","markdown":"https://secwatch.observer/filing/0001641172-25-002009.md","text":"https://secwatch.observer/filing/0001641172-25-002009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/0001641172-25-002009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225002009/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:47:43.188272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}